ASP Isotopes Inc. $ASPI Holdings Lowered by AWM Investment Company Inc.

AWM Investment Company Inc. decreased its holdings in ASP Isotopes Inc. (NASDAQ:ASPI) by 12.9% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,931,186 shares of the company’s stock after selling 580,000 shares during the period. ASP Isotopes makes up about 3.2% of AWM Investment Company Inc.’s holdings, making the stock its 6th biggest holding. AWM Investment Company Inc. owned approximately 4.69% of ASP Isotopes worth $28,934,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Ameritas Investment Partners Inc. lifted its stake in ASP Isotopes by 41.2% in the second quarter. Ameritas Investment Partners Inc. now owns 5,483 shares of the company’s stock worth $40,000 after purchasing an additional 1,600 shares during the last quarter. Perennial Advisors LLC purchased a new position in shares of ASP Isotopes in the second quarter worth about $110,000. New York State Common Retirement Fund increased its holdings in shares of ASP Isotopes by 418.2% in the second quarter. New York State Common Retirement Fund now owns 17,100 shares of the company’s stock worth $126,000 after buying an additional 13,800 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of ASP Isotopes by 9.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,840 shares of the company’s stock valued at $153,000 after acquiring an additional 1,878 shares during the last quarter. Finally, SBI Securities Co. Ltd. lifted its stake in shares of ASP Isotopes by 127.1% in the 2nd quarter. SBI Securities Co. Ltd. now owns 21,279 shares of the company’s stock valued at $157,000 after acquiring an additional 11,909 shares during the last quarter. Institutional investors own 16.80% of the company’s stock.

Insider Activity at ASP Isotopes

In related news, Director Todd Wider sold 74,108 shares of the stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $8.76, for a total value of $649,186.08. Following the completion of the transaction, the director directly owned 710,230 shares of the company’s stock, valued at $6,221,614.80. This represents a 9.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael Gorley sold 64,000 shares of the firm’s stock in a transaction dated Tuesday, September 30th. The stock was sold at an average price of $9.75, for a total transaction of $624,000.00. Following the completion of the sale, the director owned 81,360 shares of the company’s stock, valued at $793,260. This trade represents a 44.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 586,199 shares of company stock valued at $4,348,431. 14.40% of the stock is currently owned by company insiders.

ASP Isotopes Price Performance

ASPI opened at $5.94 on Friday. The company has a debt-to-equity ratio of 1.04, a quick ratio of 6.10 and a current ratio of 6.14. The stock has a market capitalization of $658.39 million, a PE ratio of -4.57 and a beta of 3.41. The stock’s 50 day moving average price is $8.37 and its 200-day moving average price is $8.69. ASP Isotopes Inc. has a 52-week low of $3.65 and a 52-week high of $14.49.

ASP Isotopes (NASDAQ:ASPI) last announced its quarterly earnings results on Wednesday, November 19th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.05). The business had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $2.25 million. ASP Isotopes had a negative return on equity of 190.44% and a negative net margin of 1,259.12%. On average, equities research analysts predict that ASP Isotopes Inc. will post -0.24 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of ASP Isotopes in a research report on Monday. Canaccord Genuity Group reissued a “buy” rating and set a $11.00 price objective on shares of ASP Isotopes in a research note on Monday, November 24th. Loop Capital set a $15.00 target price on shares of ASP Isotopes in a report on Monday, October 27th. Finally, Cantor Fitzgerald began coverage on shares of ASP Isotopes in a report on Thursday, December 4th. They set an “overweight” rating and a $13.00 price target for the company. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $13.00.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.